Anondita Medicare Ltd
Founded in March 2024, Anondita Medicare Limited manufactures flavored male condoms, with its flagship product branded as “COBRA.”[1]
- Market Cap ₹ 1,807 Cr.
- Current Price ₹ 999
- High / Low ₹ 1,227 / 262
- Stock P/E 78.7
- Book Value ₹ 60.1
- Dividend Yield 0.00 %
- ROCE %
- ROE 41.7 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 16.6 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Personal Products Personal Care
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 77 | |
| 51 | |
| Operating Profit | 26 |
| OPM % | 33% |
| 0 | |
| Interest | 3 |
| Depreciation | 1 |
| Profit before tax | 22 |
| Tax % | 25% |
| 16 | |
| EPS in Rs | 11.88 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 42% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Sep 2025 | |
|---|---|---|
| Equity Capital | 13 | 18 |
| Reserves | 25 | 91 |
| 27 | 47 | |
| 13 | 21 | |
| Total Liabilities | 78 | 176 |
| 14 | 13 | |
| CWIP | 6 | 15 |
| Investments | 3 | 3 |
| 55 | 145 | |
| Total Assets | 78 | 176 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| -10 | |
| -23 | |
| 33 | |
| Net Cash Flow | -0 |
| Free Cash Flow | -30 |
| CFO/OP | -38% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 127 |
| Inventory Days | 141 |
| Days Payable | 40 |
| Cash Conversion Cycle | 228 |
| Working Capital Days | 129 |
| ROCE % |
Insights
In beta| Jan 2026 | Mar 2027 (P) | |
|---|---|---|
| Installed Manufacturing Capacity million pieces per annum ・Standalone data |
|
|
| Capacity Under Trial Production million pieces per annum ・Standalone data |
||
| Existing Capacity Utilization million pieces per annum ・Standalone data |
||
| Existing Capacity Utilization (%) % ・Standalone data |
||
| IPO Proceeds Re-allocation to Working Capital INR Lakhs ・Standalone data |
||
| IPO Proceeds Utilized (Total) INR Lakhs ・Standalone data |
||
| IPO Unutilized Amount INR Lakhs ・Standalone data |
||
| L1 GeM Tender Supply Volume (Condoms) pieces ・Standalone data |
||
| L1 GeM Tender Supply Volume (Family Planning Items) pieces ・Standalone data |
||
| Order Value (CMSS GeM Tender) INR ・Standalone data |
||
| Projected Turnover for FY2025-26 INR Crores ・Standalone data |
||
| Target Capacity Expansion (Noida Facility) million pieces per annum ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Preferential issue
30 April 2026 - Board approved preferential issue of 2,85,000 warrants to promoter Anupam Ghosh, raising up to ₹29.13 crore.
-
Outcome of Board Meeting
30 April 2026 - Board approved 2.85 lakh promoter warrants worth ₹29.13 crore, material RPTs, remuneration hikes, and EGM.
-
Issue of Securities
30 April 2026 - Board approved 2,85,000 warrants to promoter Anupam Ghosh at ₹1,022 each, raising up to ₹29.13 crore.
-
Amendment to AOA/MOA
30 April 2026 - Board approved MOA main object change to add contraceptives, sexual wellness and gloves, subject to shareholder approval.
-
Preferential issue
30 April 2026 - Board approved 2,85,000 warrants to promoter Anupam Ghosh at Rs. 1,022 each on April 30, 2026.
Annual reports
No data available.
Concalls
-
Mar 2026TranscriptAI SummaryPPT
Business Profile:[1]
Anondita Medicare manufactures male (and recently, female) condoms, flagship brand “COBRA,” with in-house printing/packaging and 100% electronic testing.